Immune tolerance to the exogenous protein may be achieved, as has been demonstrated by Waddington et al. (18), who used factor IX in a mouse model of hemophilia B. The ability to induce tolerance to proteins to which the body is naïve is a potential advantage for clinical translation. The gene discussed is F9; the disease is hemophilia B.